Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Multiple Myeloma 108Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Leukemia 15Lymphoma 14Burkitt Lymphoma 14Recurrence 10Lymphoma, Non-Hodgkin 10Lymphoma, Mantle-Cell 10Waldenstrom Macroglobulinemia 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Immunoglobulin Light-chain Amyloidosis 8Neoplasms, Plasma Cell 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 6Smoldering Multiple Myeloma 5Neoplasms 5Lymphoma, Follicular 5Leukemia, Biphenotypic, Acute 5Hodgkin Disease 5Neoplasm Metastasis 4Nausea 4Breast Neoplasms 4Vomiting 3Renal Insufficiency 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Plasma Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hematologic Neoplasms 3Brain Neoplasms 3Blast Crisis 3

Interventions

Etoposide 3Dexamethasone 2Cyclophosphamide 2Alemtuzumab 2tocilizumab 1sintilimab 1pegaspargase 1Whole-Body Irradiation 1Vincristine 1Prednisone 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Methotrexate 1Gemcitabine 1EPOCH protocol 1Doxorubicin 1Cytarabine 1Calcium Dobesilate 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphohistiocytosis, Hemophagocytic × Calcium Dobesilate × Clear all
NCT02385110 2024-01-17

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

M.D. Anderson Cancer Center

Phase 2 Completed
18 enrolled 10 charts
MyeloidOther hematologic neoplasm

Leukemia, Lymphohistiocytosis, Hemophagocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡